Stay updated on CARDINAL Trial: Bardoxolone Methyl in Alport Syndrome
Sign up to get notified when there's something new on the CARDINAL Trial: Bardoxolone Methyl in Alport Syndrome page.

Latest updates to the CARDINAL Trial: Bardoxolone Methyl in Alport Syndrome page
- Check5 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and includes a new section on HHS Vulnerability Disclosure.SummaryDifference0.8%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.3%
- Check19 days agoChange DetectedThe web page now includes a service alert regarding planned maintenance starting July 25th, indicating that most services will be unavailable for over 24 hours beginning at 9 PM EDT.SummaryDifference4%
- Check26 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Notably, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference5%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check48 days agoChange DetectedThe page has removed references to Reata as a subsidiary of Biogen and updated the date from February 2, 2024, to June 11, 2025.SummaryDifference3%
Stay in the know with updates to CARDINAL Trial: Bardoxolone Methyl in Alport Syndrome
Enter your email address, and we'll notify you when there's something new on the CARDINAL Trial: Bardoxolone Methyl in Alport Syndrome page.